Related Experiment Video
Updated: Jun 27, 2026

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube
Published on: April 28, 2020
Management options for minimal hepatic encephalopathy
1Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, 1201 Broad Rock Boulevard, Richmond, VA 23221, USA. jasmohan.bajaj@va.gov
Abstract:
Minimal hepatic encephalopathy (MHE) is a neurocognitive dysfunction that is present in the majority of patients with cirrhosis. MHE has a characteristic cognitive profile that cannot be diagnosed clinically. This cognitive dysfunction is independent of sleep dysfunction or problems with overall intelligence. MHE has a significant impact on quality of life, the ability to function in daily life and progression to overt hepatic encephalopathy. Driving ability can be impaired in MHE and this may be a significant factor behind motor vehicle accidents. A crucial aspect of the clinical care of MHE patients is their driving history, which is often ignored during routine care and can add a vital dimension to the overall disease assessment. Driving history should be an integral part of the care of patients with MHE. The preserved communication skills and lack of specific signs and insight make MHE difficult to diagnose. The predominant strategies for MHE diagnosis are psychometric or neurophysiological testing. These are usually limited by financial, normative or time constraints. Studies into inhibitory control, cognitive drug research and critical flicker frequency tests are encouraging. These tests do not require a psychologist for administration and interpretation. Lactulose and probiotics have been studied for their potential use as therapies for MHE, but these are not standard-of-care practices at this time. Therapy can improve the quality of life in MHE patients but the natural history, specific diagnostic strategies and treatment options are still being investigated.
Insights
Minimal hepatic encephalopathy (MHE) impacts cirrhosis patients
Area of Science:
- Hepatology and Neurology
- Neuroscience
- Clinical Medicine
Background:
- Minimal hepatic encephalopathy (MHE) is a common neurocognitive dysfunction in cirrhosis patients.
- MHE presents a distinct cognitive profile, independent of sleep or general intelligence issues.
- It significantly affects quality of life, daily functioning, and progression to overt hepatic encephalopathy.
Purpose of the Study:
- To highlight the diagnostic challenges of MHE due to preserved communication and lack of insight.
- To emphasize the importance of considering driving ability and history in MHE patient assessment.
- To review current and potential diagnostic and therapeutic strategies for MHE.
Main Methods:
- Review of diagnostic approaches including psychometric and neurophysiological testing.
- Exploration of emerging diagnostic tools like inhibitory control and critical flicker frequency tests.
- Examination of potential therapies such as lactulose and probiotics.
Main Results:
- MHE impairs driving ability, a critical aspect often overlooked in clinical care.
- Standard diagnostic methods face limitations (cost, time, norms).
- Novel tests show promise for easier administration and interpretation.
Conclusions:
- Driving history is a vital, yet often neglected, component of MHE assessment.
- Accessible diagnostic tools are needed to improve MHE detection.
- Further research is required into MHE's natural history, diagnosis, and treatment.
Related Concept Videos
Hepatic Encephalopathy
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Alzheimer's Disease: Treatment
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
